(Reuters) -Rhythm Pharmaceuticals said on Monday its experimental drug to treat a rare obesity disorder met the main goal in a late-stage trial.
The therapy setmelanotide showed a significant reduction in body mass index in both adult and pediatric patients compared to placebo, the company said.
The therapy is being tested to treat acquired hypothalamic obesity, a rare form of obesity that occurs following damage to the hypothalamic region of the brain.
Rhythm estimates there are 5,000 to 10,000 people living with hypothalamic obesity in the U.S.
Setmelanotide is currently approved under the brand name Imcivree to treat genetic obesity in adults and children aged two years and older.
(Reporting by Sneha S K and Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
Comments